Apremilast Impurities and USP Related Compounds

Apremilast was approved by the US Food and Drug Administration (FDA) in 2014. Apremilast is used in treatment for psoriatic arthritis. Apremilast is also used to treat skin conditions. Apremilast is a small-molecule inhibitor of PDE4. Apremilast Degradation Impurities, Apremilast Process Impurities, Apremilast Potential Impurities, Apremilast USP Related Compound, Apremilast N-Nitroso impurities, Apremilast nitrosamine impurities etc. are listed below